{"id":32809,"date":"2021-06-03T07:00:00","date_gmt":"2021-06-03T00:00:00","guid":{"rendered":"https:\/\/www.xinwengao.com\/cn\/pr\/2021060307000032809"},"modified":"2021-06-03T21:39:11","modified_gmt":"2021-06-03T13:39:11","slug":"%e4%bf%a1%e8%be%be%e7%94%9f%e7%89%a9%e4%b8%8e%e9%a9%af%e9%b9%bf%e5%8c%bb%e7%96%97%e5%90%88%e4%bd%9c%e5%bc%80%e5%8f%91%e7%9a%84%e5%85%a8%e4%ba%ba%e6%ba%90bcma-car-t%e7%96%97%e6%b3%95%e7%a0%94%e7%a9%b6","status":"publish","type":"post","link":"https:\/\/www.xinwengao.com\/cn\/pr\/2021060307000032809","title":{"rendered":"\u4fe1\u8fbe\u751f\u7269\u4e0e\u9a6f\u9e7f\u533b\u7597\u5408\u4f5c\u5f00\u53d1\u7684\u5168\u4eba\u6e90BCMA CAR-T\u7597\u6cd5\u7814\u7a76\u6210\u679c\u83b7\u5f97\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\u300aBlood\u300b\u6742\u5fd7\u4eae\u70b9\u8ff0\u8bc4"},"content":{"rendered":"<p><p>\u7f8e\u56fd\u65e7\u91d1\u5c71\u548c\u4e2d\u56fd\u82cf\u5dde2021\u5e746\u67083\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u4fe1\u8fbe\u751f\u7269\u5236\u836f\uff08\u9999\u6e2f\u8054\u4ea4\u6240\u80a1\u7968\u4ee3\u7801\uff1a01801\uff09\uff0c\u4e00\u5bb6\u81f4\u529b\u4e8e\u7814\u53d1\u3001\u751f\u4ea7\u548c\u9500\u552e\u7528\u4e8e\u6cbb\u7597\u80bf\u7624\u3001\u4ee3\u8c22\u75be\u75c5\u3001\u81ea\u8eab\u514d\u75ab\u7b49\u91cd\u5927\u75be\u75c5\u7684\u521b\u65b0\u836f\u7269\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u4e0e\u9a6f\u9e7f\u533b\u7597\u5171\u540c\u5ba3\u5e03\uff0c\u7531\u4fe1\u8fbe\u751f\u7269\u4e0e\u9a6f\u9e7f\u533b\u7597\u5171\u540c\u5f00\u53d1\u7684\u5168\u4eba\u6e90BCMA CAR-T\u7ec6\u80de\u6ce8\u5c04\u6db2\uff08\u4fe1\u8fbe\u751f\u7269\u7814\u53d1\u4ee3\u53f7\uff1aIB1326\uff0c\u9a6f\u9e7f\u533b\u7597\u7814\u53d1\u4ee3\u53f7\uff1aCT103A\uff09\u6cbb\u7597\u590d\u53d1\/\u96be\u6cbb\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\uff08R\/R MM\uff09\u5e76\u8bc4\u4ef7\u7597\u6548\u53ca\u5b89\u5168\u6027\u7684\u4e34\u5e8a\u7814\u7a76\u521d\u6b65\u7ed3\u679c\u6b63\u5f0f\u5728\u8840\u6db2\u9886\u57df\u9876\u7ea7\u5b66\u672f\u671f\u520a\u300aBlood\u300b\u4e0a\u53d1\u8868\uff08\u201cA Phase 1 Study of a Novel Fully Human BCMA-targeting CAR (CT103A) in Patients with Relapsed\/Refractory Multiple Myeloma.\u201d\uff09\u3002\u8be5\u9879\u7814\u7a76\u4e2dIBI326\u5728\u4f53\u5185\u6301\u4e45\u5b58\u7eed\u7684\u72ec\u7279\u4f18\u52bf\u4ee5\u53ca\u4f5c\u8005\u5bf9\u4e8e\u75be\u75c5\u518d\u6cbb\u7597\u524d\u666f\u7684\u63a2\u8ba8\u5f15\u53d1\u4e86\u300aBlood\u300b\u6742\u5fd7\u7684\u9ad8\u5ea6\u5173\u6ce8\uff0c\u7f16\u8f91\u90e8\u7279\u9080\u4f26\u6566\u5927\u5b66\u5b66\u9662\u764c\u75c7\u7814\u7a76\u9662\u6743\u5a01\u4e13\u5bb6\u56e2\u961f\u5bf9\u8be5\u7814\u7a76\u6210\u679c\u53d1\u8868\u4e86\u4eae\u70b9\u8ff0\u8bc4\u300aBCMA CARs in multiple myeloma: room for more?\u300b\uff08DOI 10.1182\/blood.2021010833\uff09\u3002<\/p>\n<p><b>IBI326\u4e34\u5e8a\u7814\u7a76\u80cc\u666f\u53ca\u7ed3\u679c\uff1a<\/b><\/p>\n<p>\u76ee\u524d\uff0c\u514d\u75ab\u8c03\u8282\u836f\u7269\u3001\u86cb\u767d\u9176\u4f53\u6291\u5236\u5242\u548c\u5355\u514b\u9686\u6297\u4f53\u7b49\u521b\u65b0\u836f\u7684\u51fa\u73b0\u548c\u4e34\u5e8a\u5e94\u7528\uff0c\u663e\u8457\u6539\u5584\u4e86MM\u7684\u5b58\u6d3b\u7387\uff0c\u4f46\u96be\u6cbb\u548c\u7ecf\u8fc7\u591a\u7ebf\u6cbb\u7597\u540e\u590d\u53d1\u53d7\u8bd5\u8005\u7684\u6cbb\u7597\u4ecd\u7136\u5b58\u5728\u6781\u5927\u6311\u6218\u3002CAR-T\u7597\u6cd5\u663e\u793a\u51fa\u524d\u6240\u672a\u6709\u7684\u7597\u6548\uff0c\u4f46\u63a5\u53d7\u6297BCMA CAR-T \u7ec6\u80de\u6cbb\u7597\u7684ORR\u5dee\u522b\u8f83\u5927\u3002\u4ee5\u524d\u7684\u4e34\u5e8a\u7814\u7a76\u7ed3\u679c\u8868\u660e\uff0c33%\u81f388%\u7684R\/R MM\u53d7\u8bd5\u8005\u5728\u4f7f\u7528 BCMA CAR-T\u7ec6\u80de\u6cbb\u7597\u540e\u6709\u5ba2\u89c2\u7684\u7597\u6548\u53cd\u5e94<sup>\uff08<\/sup><sup>1-7\uff09<\/sup>\u3002\u7136\u800c\uff0c\u8981\u83b7\u5f97\u6301\u4e45\u7684\u7f13\u89e3\u4ecd\u7136\u662f\u4e00\u4e2a\u5de8\u5927\u7684\u6311\u6218\u300228% &#8211; 88%\u7684\u53d7\u8bd5\u8005\u57282 &#8211; 15\u4e2a\u6708\u7684\u4e2d\u4f4d\u968f\u8bbf\u65f6\u95f4\u51fa\u73b0\u4e86\u590d\u53d1\u6216\u75be\u75c5\u8fdb\u5c55<sup>\uff08<\/sup><sup>1-7\uff09<\/sup>\u3002<\/p>\n<p>\u6b64\u6b21\u767b\u520a\u300aBlood\u300b\u7684\u7814\u7a76\u4e3a\u4e00\u9879\u5728\u4e2d\u56fd\u8fdb\u884c\u7684\u6cbb\u7597R\/R MM\u7684\u4e34\u5e8a\u8bd5\u9a8c\u7814\u7a76\uff08ChiCTR1800018137\uff09\uff0c\u7531\u534e\u4e2d\u79d1\u6280\u5927\u5b66\u540c\u6d4e\u533b\u5b66\u9662\u9644\u5c5e\u540c\u6d4e\u533b\u9662\u8840\u6db2\u5185\u79d1\u8fdb\u884c\u3002\u7814\u7a76\u7ed3\u679c\u663e\u793a\uff1aIBI326\u5b89\u5168\u6027\u597d\uff0cCRS\u8f7b\u5fae\u53ef\u63a7\u3002\u540c\u65f6\uff0cIBI326\u56de\u8f93\u5230\u4f53\u5185\u540e\u5747\u51fa\u73b0\u4e86\u826f\u597d\u7684\u6269\u589e\uff0c\u5927\u591a\u6570\u6301\u7eed\u65f6\u95f4\u8f83\u957f\u3002\u6b64\u5916\uff0c\u5bf9\u65e2\u5f80\u63a5\u53d7\u8fc7\u975e\u4eba\u6e90 BCMA CAR-T\u6cbb\u7597\u540e\u590d\u53d1\u6216\u8005\u75be\u75c5\u8fdb\u5c55\u7684\u53d7\u8bd5\u8005\uff0cIBI326\u4e5f\u5747\u663e\u793a\u51fa\u826f\u597d\u7684\u7597\u6548\u3002<\/p>\n<p><b>\u5728\u6709\u6548\u6027\u65b9\u9762\uff1a<\/b><\/p>\n<ul type=\"disc\">\n<li>IBI326\u5728R\/RMM\u53d7\u8bd5\u8005\u4e2d\u662f\u4e00\u79cd\u5177\u6709\u9ad8\u5ea6\u6d3b\u6027\u4e14\u8d77\u6548\u5feb\u7684CAR-T\u7597\u6cd5\u300218\u4f8b\u53d7\u8bd5\u8005\u7684 ORR \u4e3a100%\uff0c\u5b8c\u5168\u7f13\u89e3\uff08CR\uff09\/ \u4e25\u683c\u610f\u4e49\u7684\u5b8c\u5168\u7f13\u89e3(sCR)\u4e3a72.2%\u3002\u56de\u8f93\u540e1\u4e2a\u6708\uff0c\u53ef\u8bc4\u4f30MRD\u768417\u4f8b\u53d7\u8bd5\u8005\u5747\u8fbe\u5230\u9634\u6027\uff0810-4 FCM\uff09\u3002\u5176\u4e2d\u67099\u4f8b\u53d7\u8bd5\u8005\u91c7\u7528\u4e86NGS\u68c0\u6d4bMRD\uff0810-6\uff09\uff0c\u67094\u4f8b\u53d7\u8bd5\u8005\u8fbe\u5230\u9634\u6027\u3002\u6240\u6709\u5165\u7ec4\u53d7\u8bd5\u8005\u76841\u5e74PFS\u7387\u4e3a58.3%\uff0cOS\u7387\u4e3a75%\uff0c\u65e0\u9ad3\u5916\u75c5\u7076\u9aa8\u9ad3\u7624\u53d7\u8bd5\u8005\uff08EMM\uff09\u76841\u5e74PFS\u7387\u8fbe\u523079.1%\u3002\u5230\u76ee\u524d\u4e3a\u6b62\uff0c\u968f\u8bbf\u65f6\u95f4\u6700\u957f\u76841\u4f8b\u53d7\u8bd5\u8005\u7684sCR \u72b6\u6001\u5df2\u7ecf\u8d85\u8fc72\u5e74\u3002 <\/li>\n<li>\u65e2\u5f80\u63a5\u53d7\u5c0f\u9f20BCMA CAR-T\u6cbb\u7597\u7684\u53d7\u8bd5\u8005\u4ecd\u7136\u53ef\u4eceIBI326\u4e2d\u83b7\u76ca\u30024\u4f8b\u7ecf\u8fc7\u5f02\u6e90CAR-T\u6cbb\u7597\u540e\u590d\u53d1\u7684\u53d7\u8bd5\u8005\uff0c3\u4f8b\u8fbe\u5230CR\/sCR\uff0c1\u4f8b\u8fbe\u5230VGPR\u3002<\/li>\n<\/ul>\n<p>\u5728\u5b89\u5168\u6027\u65b9\u9762\uff1a\u6240\u6709\u5242\u91cf\u7ec4\u5747\u672a\u89c2\u5bdf\u5230\u514d\u75ab\u6548\u5e94\u7ec6\u80de\u76f8\u5173\u795e\u7ecf\u6bd2\u6027\u7efc\u5408\u5f81\uff08ICANS\uff09\u300294%\u7684\u53d7\u8bd5\u8005\u51fa\u73b0\u4e86\u7ec6\u80de\u56e0\u5b50\u91ca\u653e\u7efc\u5408\u5f81 (CRS)\uff0c\u5176\u4e2d\u22653\u7ea7\u7684CRS \u7684\u53d1\u751f\u7387\u4e3a28%\uff1b\u6392\u9664\u6700\u9ad8\u5242\u91cf\u7ec46X106\/kg\uff0c \u5219\u22653 \u7ea7CRS\u7684\u53d1\u751f\u7387\u4ec5\u4e3a13%\u3002\u5728\u540e\u7eed\u7814\u7a76\u4e2d\uff0c1 X106\/kg\u5242\u91cf\u4e3a\u4e8c\u671f\u7814\u7a76\u7684\u63a8\u8350\u5242\u91cf\u3002<\/p>\n<p>\u5728CAR-T\u7ec6\u80de\u6269\u589e\u65b9\u9762\uff1a\u901a\u8fc7\u6570\u5b57PCR\u6280\u672f\u68c0\u6d4b\uff0c\u7ed3\u679c\u663e\u793a\u5728\u56de\u8f93\u540e\u4e2d\u4f4d\u65f6\u95f412\u5929\u65f6\uff0cCAR-T\u7ec6\u80de\u6269\u589e\u8fbe\u5230\u9ad8\u5cf0\uff0c\u5404\u4e2a\u5242\u91cf\u7ec4\u7684PK\u53c2\u6570\u65e0\u663e\u8457\u6027\u5dee\u5f02\uff0c\u5747\u663e\u793a\u826f\u597d\u7684\u6269\u589e\u3002\u540c\u65f6\u68c0\u6d4b4\u4f8b\u5f02\u6e90CAR-T\u6cbb\u7597\u540e\u8fdb\u5c55\u53d7\u8bd5\u8005\u7684\u5168\u4eba\u6e90\u53ca\u5f02\u6e90CAR-T\u7ec6\u80de\uff0c\u7ed3\u679c\u663e\u793a\u5168\u4eba\u6e90CAR-T\u6269\u589e\u826f\u597d\uff0c\u800c\u5f02\u6e90CAR-T\u6269\u589e\u65f6\u95f4\u77ed\uff0c\u5e45\u5ea6\u5f88\u4f4e\uff0c\u63d0\u793a\u8fd94\u4f8b\u53d7\u8bd5\u8005\u7684\u7597\u6548\u662fIBI326\u53d1\u6325\u7684\u4f5c\u7528\u3002<\/p>\n<p>\u5728\u514d\u75ab\u539f\u6027\u65b9\u9762\uff1a\u5bf918\u4f8b\u53d7\u8bd5\u8005\u7684ADA\u7684\u6c34\u5e73\u8fdb\u884c\u68c0\u6d4b\uff0c\u53ea\u67091\u4f8b\u53d7\u8bd5\u8005\u89c2\u5bdf\u5230\u9633\u6027\u3002<\/p>\n<p><b>\u300a<\/b><b>Blood\u300b\u8ff0\u8bc4\u7cbe\u534e\uff1a<\/b><\/p>\n<p>\u5728\u8ff0\u8bc4\u6587\u7ae0\u4e2d\uff0c\u6765\u81ea\u4f26\u6566\u5927\u5b66\u5b66\u9662\uff08UCL\uff09\u764c\u75c7\u7814\u7a76\u9662\u76843\u4f4d\u4e13\u5bb6Lydia Sarah \u3001Hui Lee\u548c Kwee L. Yong\u5bf9IBI326\u7684\u7814\u7a76\u7ed3\u679c\u548c\u63a2\u8ba8\u65b9\u5411\u8868\u793a\u4e86\u5173\u6ce8\u548c\u80af\u5b9a\u3002\u201c\u8be5\u4e34\u5e8a\u7ed3\u679c\u6b63\u662f\u6211\u4eec\u5728CAR\uff0dT\u6cbb\u7597\u9886\u57df\u6240\u671f\u5f85\u5b9e\u73b0\u7684\u3002\u4e3a\u4e86\u4fbf\u4e8e\u4e0e\u5168\u7403\u5176\u5b83\u8bd5\u9a8c\u8fdb\u884c\u5168\u9762\u5bf9\u6bd4\uff0c\u7814\u7a76\u8005\u5bf9CT103\uff08\u8ff0\u8bc4\u4e2d\u4f5c\u8005\u5bf9IBI326\u7684\u7b80\u79f0\u4e3a\u201cCT103\u201d\uff09\u7684\u7814\u7a76\u65b9\u6848\u548c\u53d7\u8bd5\u8005\u961f\u5217\u4fe1\u606f\u4e5f\u505a\u4e86\u8be6\u7ec6\u9610\u8ff0\uff0c\u8bc4\u4f30\u975e\u5e38\u5ba2\u89c2\u3002\u66f4\u91cd\u8981\u7684\u662f\uff0c\u8be5\u7814\u7a76\u6709\u5f88\u591a\u4eae\u70b9\u4e4b\u5904\uff0c\u5982CAR-T \u5728\u4f53\u5185\u7684\u5b58\u7eed\u65f6\u95f4\uff0c\u4ee5\u53ca\u7eb3\u5165\u4e86\u65e2\u5f80\u63a5\u53d7\u8fc7\u9f20\u6e90BCMA CAR-T\u6cbb\u7597\u590d\u53d1\u7684\u53d7\u8bd5\u8005\u3002\u201d<\/p>\n<p>\u8ff0\u8bc4\u4e2d\uff0c\u4e13\u5bb6\u63d0\u51fa\uff1a\u6297CD19 CAR-T\u7ec6\u80de\u7597\u6cd5\u53ef\u4f7f40%\u7684\u96be\u6cbb\/\u591a\u6b21\u590d\u53d1\u7684\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08ALL\uff09\u53d7\u8bd5\u8005\u83b7\u5f97\u6301\u4e45\u7f13\u89e3 <sup>\uff08<\/sup><sup>8\uff09<\/sup>\u3002\u76f8\u6bd4\u4e4b\u4e0b\uff0c\u65e2\u5f80\u7814\u7a76\u4e2d\u7684CAR-T\u7ec6\u80de\u7597\u6cd5\u5728\u6cbb\u7597MM\u65b9\u9762\uff0c\u5c3d\u7ba1\u6cbb\u7597\u521d\u671f\u53ef\u4ee5\u89c2\u5bdf\u5230\u7597\u6548\uff0c\u5374\u672a\u80fd\u5b9e\u73b0\u6301\u4e45\u7f13\u89e3<sup>\uff08<\/sup><sup>9-11\uff09<\/sup>\u3002\u6700\u65e9\u76842\u9879BCMA CAR-T\u8bd5\u9a8c\u6240\u62a5\u544a\u7684\u53d7\u8bd5\u8005\u4e2d\u4f4d\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\u5c0f\u4e8e\u4e00\u5e74\u3002 \u5c3d\u7ba1\u540c\u7c7b\u836f\u7269\u7684\u7814\u7a76\u5c55\u73b0\u4e86\u5f88\u597d\u7684\u6cbb\u7597\u7ed3\u679c\uff0c\u4f46\u76ee\u524d\u5c1a\u4e0d\u6e05\u695a\u73b0\u6709\u7684 CAR -T\u7597\u6cd5\u80fd\u5426\u4e3aMM\u53d7\u8bd5\u8005\u5e26\u6765\u957f\u671f\u7f13\u89e3\u3002<\/p>\n<p>\u968f\u540e\uff0c\u4e13\u5bb6\u5bf9IBI326\u6240\u5c55\u793a\u51fa\u7684\u4f53\u5185\u5b58\u7eed\u4f18\u52bf\u8868\u793a\u4e86\u5173\u6ce8\u4e0e\u80af\u5b9a\u3002\u4f5c\u8005\u5bf9\u6bd4\u4e86CT103\u4e0e\u5df2\u4e0a\u5e02\u76842\u6b3eCAR-T\u836f\u7269\u7684\u4e34\u5e8a\u6570\u636e\u3002\u201c\u5728\u6700\u65e9\u8bc4\u4f30 BCMA CART \u7684bb2121 \u548c LCAR-B38M\/JNJ- 4528\u4e24\u9879\u8bd5\u9a8c\u4e2d\uff0cCAR-T\u7ec6\u80de\u5728\u4f53\u5185\u7684\u5b58\u7eed\u65f6\u95f4\u901a\u5e38\u22646\u4e2a\u6708<sup>\uff08<\/sup><sup>9-11<\/sup><sup>\uff09<\/sup>\uff0c\u4e5f\u6b63\u56e0\u4e3a\u8fd9\u6837\u7684\u7ed3\u679c\uff0cCT103\u6240\u5c55\u793a\u51fa\u7684\u6301\u4e45\u5b58\u7eed\u6027\u663e\u5f97\u683c\u5916\u5f15\u4eba\u6ce8\u76ee\u3002\u6211\u4eec\u770b\u5230\uff0c\u5c3d\u7ba1\u5faa\u73af CT103 \u7684\u6700\u5927\u6d53\u5ea6\u4f4e\u4e8e\u5176\u4ed6CAR-T\u7597\u6cd5\u6240\u62a5\u544a\u7684\u6d53\u5ea6<sup>\uff08<\/sup><sup>10<\/sup><sup>\uff09<\/sup>\uff0c\u4f46\u5b83\u6240\u5e26\u6765\u7684\u4e2d\u4f4d\u6301\u7eed\u65f6\u95f4\u622a\u6b62\u968f\u8bbf\u671f\u4e3a&nbsp;308 \u5929\uff0c\u4e14\u8fd9\u4e00\u7ed3\u679c\u53ef\u80fd\u4f1a\u968f\u7740\u540e\u671f\u968f\u8bbf\u800c\u589e\u52a0\u3002\u6211\u4eec\u5728\u6240\u6709\u53d7\u8bd5\u8005\u4e2d\u90fd\u89c2\u5bdf\u5230\u4e86T\u7ec6\u80de\u7684\u5f3a\u52b2\u6269\u589e\uff0c\u5728\u6700\u540e\u4e00\u6b21\u968f\u8bbf\u65f6\uff08\u4e2d\u4f4d\u968f\u8bbf\u65f6\u95f4\u4e3a13\u4e2a\u6708\uff09\uff0c\u53ea\u6709 5 \u540d\u53d7\u8bd5\u8005\u7684 CAR- T\u57fa\u56e0\u62f7\u8d1d\u6570\u4f4e\u4e8e1X 10&sup2; copies\/ug gDNA\u3002<\/p>\n<p>\u9664\u4e86\u8f83\u9ad8\u7684\u4f53\u5185\u6301\u7eed\u6027\uff0c\u4e13\u5bb6\u4eec\u4e5f\u5bf9CT103\u5177\u6709\u76f8\u5bf9\u8f83\u4f4e\u7684\u7ed3\u5408\u4eb2\u548c\u529b(10 nM)\u7684\u7279\u70b9\u8868\u793a\u4e86\u5173\u6ce8\u3002\u201c\u4e0etisagenle cleucel \u548c&nbsp;axicabtagene ciloleucel\uff08\u5373\u4ee5FMC63\u4e3ascFv\u5e8f\u5217\uff09\u7684\u9776\u5411CD19\u7684CAR-T\u7597\u6cd5\u76f8\u6bd4\uff0cCT103 \u7684\u7ed3\u5408\u901f\u7387\u66f4\u6162\uff0c\u4f46\u5374\u5177\u6709\u7c7b\u4f3c\u7684\u5feb\u901f\u89e3\u79bb\u901f\u7387\u3002\u4eb2\u548c\u529b\u4e0e\u4e34\u5e8a\u7ed3\u679c\u4e4b\u95f4\u662f\u5426\u5b58\u5728\u76f8\u5173\u6027\u76ee\u524d\u4ecd\u4e0d\u786e\u5b9a\uff0c\u8fd9\u53ef\u80fd\u53d6\u51b3\u4e8e\u5bf9\u6cbb\u7597\u9776\u70b9\u548c\u5176\u5b83\u5177\u4f53\u60c5\u51b5\u7684\u5206\u6790\u3002&nbsp;\u5728\u4ee5CD19\u4e3a\u9776\u70b9\u7684CAR-T\u6cbb\u7597\u4e2d\uff0c\u4f4e\u4eb2\u548c\u529b\u7684CAR \u53ef\u63d0\u5347\u5176\u5728\u513f\u7ae5ALL\u53d7\u8bd5\u8005\u4f53\u5185\u5b58\u6d3b\u7684\u6301\u7eed\u6027<sup>\uff08<\/sup><sup>12<\/sup><sup>\uff09<\/sup>\uff0c\u4f5c\u8005\u63a8\u6d4b\u8f83\u5feb\u7684\u89e3\u79bb\u901f\u7387\u53ef\u80fd\u6709\u52a9\u4e8eCAR-T\u7ec6\u80de\u7684\u8fde\u7eed\u6fc0\u6d3b\u3002\u9488\u5bf9\u7ed3\u5408\u52a8\u529b\u5b66\u662f\u5426\u4f1a\u5bf9BCMA CAR\u7684\u7597\u6548\u5e26\u6765\u600e\u6837\u7684\u5f71\u54cd\uff0c\u8fd8\u9700\u5f00\u5c55\u66f4\u8fdb\u4e00\u6b65\u7684\u7814\u7a76\u3002\u201d<\/p>\n<p>\u6b64\u5916\uff0c\u8ff0\u8bc4\u4e13\u5bb6\u8fd8\u63d0\u5230\u4e86CT103\u7814\u7a76\u7684\u53e6\u4e00\u4e2a\u4e0e\u4f17\u4e0d\u540c\u4e4b\u5904\u662f\u62db\u52df\u4e86&nbsp;4 \u540d\u5148\u524d\u63a5\u53d7\u8fc7\u9f20\u6e90&nbsp;BCMA CAR-T\u6cbb\u7597\u7684\u53d7\u8bd5\u8005\u3002\u201cCT103 \u5728\u6240\u6709&nbsp;4 \u540d\u53d7\u8bd5\u8005\u4e2d\u5747\u51fa\u73b0\u4e86\u6269\u589e\uff0c\u5176\u4e2d&nbsp;3 \u540d\u5728\u6e05\u6dcb\u9884\u5904\u7406\u540e\u9f20\u6e90BCMA CAR\u6784\u5efa\u4f53\u51fa\u73b0\u4e86\u77ed\u6682\u7684\u4f4e\u6c34\u5e73\u6269\u589e\u3002\u8fd9\u8868\u660e\u5728\u51fa\u73b0\u6297\u539f\u4e3a\u9633\u6027\u7684\u75be\u75c5\u590d\u53d1\u65f6\u8fd8\u6709\u672a\u68c0\u6d4b\u5230\u7684&nbsp;CAR -T \u7ec6\u80de\u5b58\u5728\uff0c\u4f46\u8fd9\u4e9b\u7ec6\u80de\u53ef\u80fd\u4f1a\u88ab\u8017\u5c3d\u6216\u6700\u7ec8\u88ab\u5206\u5316\u3002CT103\u7814\u7a76\u8fd8\u9610\u8ff0\u4e86\u4f7f\u7528&nbsp;CAR-T\u7597\u6cd5\u5bf9\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u8fdb\u884c\u518d\u6cbb\u7597\u7684\u53ef\u80fd\u6027\u3002\u4e86\u89e3\u5bfc\u81f4\u590d\u53d1\u548c\u6cbb\u7597\u5931\u8d25\u7684\u56e0\u7d20\u80fd\u591f\u5e2e\u52a9\u6211\u4eec\u4e3a\u8fdb\u4e00\u6b65\u6cbb\u7597\u627e\u5230\u66f4\u52a0\u79d1\u5b66\u5408\u7406\u7684\u65b9\u6cd5\u3002\u201d<\/p>\n<p>\u8ff0\u8bc4\u6700\u540e\uff0c\u4f26\u6566\u5927\u5b66\u5b66\u9662\u764c\u75c7\u7814\u7a76\u6743\u5a01\u4e13\u5bb6\u4eec\u5bf9IBI326\u7684\u6301\u4e45\u5b58\u7eed\u6027\u4ee5\u53caMM\u75be\u75c5\u7684\u6cbb\u7597\u7ed9\u4e88\u4e86\u80af\u5b9a\u4e0e\u5c55\u671b\uff1a\u201c\u4ece\u66f4\u5927\u7684\u5c42\u9762\u6765\u770b\uff0c\u6211\u4eec\u6b63\u5728\u89c1\u8bc1&nbsp;MM CAR-T \u7ec6\u80de\u7597\u6cd5\u7684\u5feb\u901f\u53d1\u5c55\u3002\u6211\u4eec\u671f\u5f85\u8d8a\u6765\u8d8a\u591a\u7684CAR-T\u7597\u6cd5\u5728\u5168\u7403\u89d2\u9010\u4e00\u5e2d\u4e4b\u5730\u7684\u540c\u65f6\u80fd\u7ed9\u6211\u4eec\u5e26\u6765\u975e\u5e38\u6709\u5e0c\u671b\u7684\u65e9\u671f\u8bd5\u9a8c\u6570\u636e\uff0c\u6bd4\u5982\u5728\u6301\u4e45\u5b58\u7eed\u6027\u65b9\u9762\uff0c\u4e00\u4e9b\u7597\u6cd5\u53ef\u5177\u5907\u4e0eCT103\u76f8\u5f53\u7684\u5b9e\u529b<sup>\uff08<\/sup><sup>13<\/sup><sup>\uff09<\/sup>\u3002\u56e0\u6b64\uff0c\u867d\u7136CT103\u6b63\u5904\u5728\u4e00\u4e2a\u7ade\u4e89\u6fc0\u70c8\u7684\u8d5b\u9053\u4e0a\uff0c&nbsp;\u4f46\u56e0\u4e3aCT103\u5728\u4f53\u5185\u6301\u4e45\u7eed\u5b58\u6240\u5c55\u793a\u51fa\u7684\u72ec\u7279\u4f18\u52bf\u4ee5\u53caCT103\u6240\u5f15\u53d1\u7684\u5bf9\u4e8eCAR-T\u7597\u6cd5\u6cbb\u7597\u5931\u8d25\u540e\u518d\u6cbb\u7597\u524d\u666f\u7684\u63a2\u8ba8\uff0c\u4f7f\u5f97\u5b83\u6210\u4e3a\u8fd9\u6761\u8d5b\u9053\u4e0a\u4e0d\u53ef\u6216\u7f3a\u7684\u4e00\u4efd\u5b50\u3002\u201d<\/p>\n<div>\n<table id=\"convertedTable035f\" cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prnsbt0 prnsbr0 prnbcc prnsbb0 prnsbl0\">\n<tbody>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">\u53c2\u8003\u6587\u732e\uff1a<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">1. Ali SA, Shi V, Maric I, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128(13):1688-1700.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">2. Xu J, Wang Q, Xu H, et al. Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma. J Hematol Oncol. 2018;11(1):128.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">3.Zhao WH, Liu J, Wang BY, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018;11(1):141.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">4. Brudno JN, Maric I, Hartman SD, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018;36(22): 2267-2280.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">5. Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019; 380(18):1726-1737.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">6. Xu J, Chen LJ, Yang SS, et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma. Proc Natl Acad Sci U S A. 2019; 116(19):9543-9551.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">7. Cohen AD, Garfall AL, Stadtmauer EA, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 2019;129(6):2210-2221.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">8.Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439-448<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">9.Brudno JN, Maric I, Hartman SD, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018;36(22): 2267-2280.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">10. Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019; 380(18):1726-1737.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">11. Madduri D, Berdeja JG, Usmani SZ, et al CARTITUDE-1: Phase 1b\/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen\u2013directed chimeric antigen receptor T cell therapy, in relapsed\/refractory multiple myeloma [abstract]. Blood. 2020;136(suppl 1). Abstract 177.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">12\uff0eGhorashian S, Kramer AM, Onuoha S, et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med. 2019;25(9):1408-1414.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">13. Mailankody S, Jakubowiak AJ, Htut M, et alOrvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed\/ refractory multiple myeloma (RRMM): update of the phase 1\/2 EVOLVE study (NCT03430011) [abstract]. J Clin Oncol. 2020; 38(suppl 15). Abstract 8504.<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p>\u76f8\u5173\u94fe\u63a5 :<\/p>\n<p>http:\/\/www.innoventbio.com<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u7f8e\u56fd\u65e7\u91d1\u5c71\u548c\u4e2d\u56fd\u82cf\u5dde2021\u5e746\u67083\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u4fe1\u8fbe\u751f\u7269\u5236\u836f\uff08\u9999\u6e2f\u8054\u4ea4\u6240\u80a1\u7968\u4ee3\u7801\uff1a01801\uff09\uff0c\u4e00\u5bb6\u81f4\u529b\u4e8e\u7814\u53d1\u3001\u751f\u4ea7\u548c\u9500\u552e\u7528\u4e8e\u6cbb\u7597\u80bf\u7624\u3001\u4ee3\u8c22\u75be\u75c5\u3001\u81ea\u8eab\u514d\u75ab\u7b49\u91cd\u5927\u75be\u75c5\u7684\u521b\u65b0\u836f\u7269\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u4e0e\u9a6f\u9e7f\u533b\u7597\u5171\u540c\u5ba3\u5e03\uff0c\u7531\u4fe1\u8fbe\u751f\u7269\u4e0e\u9a6f\u9e7f\u533b\u7597\u5171\u540c\u5f00\u53d1\u7684\u5168\u4eba\u6e90BCMA CAR-T\u7ec6\u80de\u6ce8\u5c04\u6db2\uff08\u4fe1\u8fbe\u751f\u7269\u7814\u53d1\u4ee3\u53f7\uff1aIB1326\uff0c\u9a6f\u9e7f\u533b\u7597\u7814\u53d1\u4ee3\u53f7\uff1aCT103A\uff09\u6cbb\u7597\u590d\u53d1\/\u96be\u6cbb\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\uff08R\/R MM\uff09\u5e76\u8bc4\u4ef7\u7597\u6548\u53ca\u5b89\u5168\u6027\u7684\u4e34\u5e8a\u7814\u7a76\u521d\u6b65\u7ed3\u679c\u6b63\u5f0f\u5728\u8840\u6db2\u9886\u57df\u9876\u7ea7\u5b66\u672f\u671f\u520a\u300aBlood\u300b\u4e0a\u53d1\u8868\uff08\u201cA Phase 1 Study of a Novel Fully Human BCMA-targeting CAR (CT103A) in Patients with Relapsed\/Refractory Multiple Myeloma.\u201d\uff09\u3002\u8be5\u9879\u7814\u7a76\u4e2dIBI326\u5728\u4f53\u5185\u6301\u4e45\u5b58\u7eed\u7684\u72ec\u7279\u4f18\u52bf\u4ee5\u53ca\u4f5c\u8005\u5bf9\u4e8e\u75be\u75c5\u518d\u6cbb\u7597\u524d\u666f\u7684\u63a2\u8ba8\u5f15\u53d1\u4e86\u300aBlood\u300b\u6742\u5fd7\u7684\u9ad8\u5ea6\u5173\u6ce8\uff0c\u7f16\u8f91\u90e8\u7279\u9080\u4f26\u6566\u5927\u5b66\u5b66\u9662\u764c\u75c7\u7814\u7a76\u9662\u6743\u5a01\u4e13\u5bb6\u56e2\u961f\u5bf9\u8be5\u7814\u7a76\u6210\u679c\u53d1\u8868\u4e86\u4eae\u70b9\u8ff0\u8bc4\u300aBCMA CARs in multiple myeloma: room for more?\u300b\uff08DOI 10.1182\/blood.2021010833\uff09\u3002 IBI326\u4e34\u5e8a\u7814\u7a76\u80cc\u666f\u53ca\u7ed3\u679c\uff1a \u76ee\u524d\uff0c\u514d\u75ab\u8c03\u8282\u836f\u7269\u3001\u86cb\u767d\u9176\u4f53\u6291\u5236\u5242\u548c\u5355\u514b\u9686\u6297\u4f53\u7b49\u521b\u65b0\u836f\u7684\u51fa\u73b0\u548c\u4e34\u5e8a\u5e94\u7528\uff0c\u663e\u8457\u6539\u5584\u4e86MM\u7684\u5b58\u6d3b\u7387\uff0c\u4f46\u96be\u6cbb\u548c\u7ecf\u8fc7\u591a\u7ebf\u6cbb\u7597\u540e\u590d\u53d1\u53d7\u8bd5\u8005\u7684\u6cbb\u7597\u4ecd\u7136\u5b58\u5728\u6781\u5927\u6311\u6218\u3002CAR-T\u7597\u6cd5\u663e\u793a\u51fa\u524d\u6240\u672a\u6709\u7684\u7597\u6548\uff0c\u4f46\u63a5\u53d7\u6297BCMA CAR-T \u7ec6\u80de\u6cbb\u7597\u7684ORR\u5dee\u522b\u8f83\u5927\u3002\u4ee5\u524d\u7684\u4e34\u5e8a\u7814\u7a76\u7ed3\u679c\u8868\u660e\uff0c33%\u81f388%\u7684R\/R MM\u53d7\u8bd5\u8005\u5728\u4f7f\u7528 BCMA CAR-T\u7ec6\u80de\u6cbb\u7597\u540e\u6709\u5ba2\u89c2\u7684\u7597\u6548\u53cd\u5e94\uff081-7\uff09\u3002\u7136\u800c\uff0c\u8981\u83b7\u5f97\u6301\u4e45\u7684\u7f13\u89e3\u4ecd\u7136\u662f\u4e00\u4e2a\u5de8\u5927\u7684\u6311\u6218\u300228% &#8211; 88%\u7684\u53d7\u8bd5\u8005\u57282 &#8211; 15\u4e2a\u6708\u7684\u4e2d\u4f4d\u968f\u8bbf\u65f6\u95f4\u51fa\u73b0\u4e86\u590d\u53d1\u6216\u75be\u75c5\u8fdb\u5c55\uff081-7\uff09\u3002 \u6b64\u6b21\u767b\u520a\u300aBlood\u300b\u7684\u7814\u7a76\u4e3a\u4e00\u9879\u5728\u4e2d\u56fd\u8fdb\u884c\u7684\u6cbb\u7597R\/R MM\u7684\u4e34\u5e8a\u8bd5\u9a8c\u7814\u7a76\uff08ChiCTR1800018137\uff09\uff0c\u7531\u534e\u4e2d\u79d1\u6280\u5927\u5b66\u540c\u6d4e\u533b\u5b66\u9662\u9644\u5c5e\u540c\u6d4e\u533b\u9662\u8840\u6db2\u5185\u79d1\u8fdb\u884c\u3002\u7814\u7a76\u7ed3\u679c\u663e\u793a\uff1aIBI326\u5b89\u5168\u6027\u597d\uff0cCRS\u8f7b\u5fae\u53ef\u63a7\u3002\u540c\u65f6\uff0cIBI326\u56de\u8f93\u5230\u4f53\u5185\u540e\u5747\u51fa\u73b0\u4e86\u826f\u597d\u7684\u6269\u589e\uff0c\u5927\u591a\u6570\u6301\u7eed\u65f6\u95f4\u8f83\u957f\u3002\u6b64\u5916\uff0c\u5bf9\u65e2\u5f80\u63a5\u53d7\u8fc7\u975e\u4eba\u6e90 BCMA CAR-T\u6cbb\u7597\u540e\u590d\u53d1\u6216\u8005\u75be\u75c5\u8fdb\u5c55\u7684\u53d7\u8bd5\u8005\uff0cIBI326\u4e5f\u5747\u663e\u793a\u51fa\u826f\u597d\u7684\u7597\u6548\u3002 \u5728\u6709\u6548\u6027\u65b9\u9762\uff1a IBI326\u5728R\/RMM\u53d7\u8bd5\u8005\u4e2d\u662f\u4e00\u79cd\u5177\u6709\u9ad8\u5ea6\u6d3b\u6027\u4e14\u8d77\u6548\u5feb\u7684CAR-T\u7597\u6cd5\u300218\u4f8b\u53d7\u8bd5\u8005\u7684 ORR \u4e3a100%\uff0c\u5b8c\u5168\u7f13\u89e3\uff08CR\uff09\/ \u4e25\u683c\u610f\u4e49\u7684\u5b8c\u5168\u7f13\u89e3(sCR)\u4e3a72.2%\u3002\u56de\u8f93\u540e1\u4e2a\u6708\uff0c\u53ef\u8bc4\u4f30MRD\u768417\u4f8b\u53d7\u8bd5\u8005\u5747\u8fbe\u5230\u9634\u6027\uff0810-4 FCM\uff09\u3002\u5176\u4e2d\u67099\u4f8b\u53d7\u8bd5\u8005\u91c7\u7528\u4e86NGS\u68c0\u6d4bMRD\uff0810-6\uff09\uff0c\u67094\u4f8b\u53d7\u8bd5\u8005\u8fbe\u5230\u9634\u6027\u3002\u6240\u6709\u5165\u7ec4\u53d7\u8bd5\u8005\u76841\u5e74PFS\u7387\u4e3a58.3%\uff0cOS\u7387\u4e3a75%\uff0c\u65e0\u9ad3\u5916\u75c5\u7076\u9aa8\u9ad3\u7624\u53d7\u8bd5\u8005\uff08EMM\uff09\u76841\u5e74PFS\u7387\u8fbe\u523079.1%\u3002\u5230\u76ee\u524d\u4e3a\u6b62\uff0c\u968f\u8bbf\u65f6\u95f4\u6700\u957f\u76841\u4f8b\u53d7\u8bd5\u8005\u7684sCR \u72b6\u6001\u5df2\u7ecf\u8d85\u8fc72\u5e74\u3002 \u65e2\u5f80\u63a5\u53d7\u5c0f\u9f20BCMA CAR-T\u6cbb\u7597\u7684\u53d7\u8bd5\u8005\u4ecd\u7136\u53ef\u4eceIBI326\u4e2d\u83b7\u76ca\u30024\u4f8b\u7ecf\u8fc7\u5f02\u6e90CAR-T\u6cbb\u7597\u540e\u590d\u53d1\u7684\u53d7\u8bd5\u8005\uff0c3\u4f8b\u8fbe\u5230CR\/sCR\uff0c1\u4f8b\u8fbe\u5230VGPR\u3002&hellip; <a class=\"read-more\" href=\"https:\/\/www.xinwengao.com\/cn\/pr\/2021060307000032809\">Read More<\/a><\/p>\n","protected":false},"author":556,"featured_media":8278,"comment_status":"close","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1965],"tags":[],"class_list":["post-32809","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-partnerships"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/32809","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/comments?post=32809"}],"version-history":[{"count":1,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/32809\/revisions"}],"predecessor-version":[{"id":32810,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/32809\/revisions\/32810"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media\/8278"}],"wp:attachment":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media?parent=32809"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/categories?post=32809"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/tags?post=32809"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}